Pollock, Kevin G.
Dickerson, Carissa
Kainth, Manjit
Lawton, Sarah
Hurst, Michael
Sugrue, Daniel M.
Arden, Chris
Davies, D. Wyn
Martin, Anne-Céline
Sandler, Belinda
Gordon, Jason
Farooqui, Usman
Clifton, David
Mallen, Christian
Rogers, Jennifer
Hill, Nathan R.
Camm, A. John
Cohen, Alexander T.
Funding for this research was provided by:
Bristol-Myers Squibb Ltd
Pfizer Inc.
Article History
Received: 23 February 2023
Accepted: 14 December 2023
First Online: 2 January 2024
Declarations
:
: The study complies with the Declaration of Helsinki. Ethical approval was granted by the Wales Research Ethics Committee 5 and the study was approved by the Health Research Authority (HRA) and Health and Care Research Wales (HCRW) (IRAS project ID: 252934). All participants provided verbal informed consent prior to participating in the interview/focus group sessions for this reflection exercise.
: Not applicable.
: A. John Camm has received institutional grants and personal fees from Bayer, Boehringer Ingelheim, Bristol Myers Squibb/Pfizer Alliance and Daiichi Sankyo. Anne-Céline Martin has received consulting fees and a research grant from Bristol Myers Squibb/Pfizer Alliance, and consulting fees from Bayer-Healthcare and Boehringer-Ingelheim. David Clifton declares fees from Oxford University Innovation, Biobeats, Bristol Myers Squibb, Sensyne Health and academic research grants from GlaxoSmithKline, AstraZeneca, Apple, RCUK, Wellcome Trust, EU Horizon2020, and NIHR. Alexander Cohen receives consulting fees from AbbVie, ACI Clinical, Alexion, Aspen, Astra Zeneca, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Boston Scientific, CSL Behring, Daiichi-Sankyo, GlaxoSmithKline, GLG, Guidepoint Global, Johnson and Johnson, Leo Pharma, Medscape, McKinsey, Navigant, ONO, Pfizer, Portola, Sanofi, TRN; advisory board membership with Bayer, Bristol Myers Squibb, Daiichi-Sankyo, Johnson and Johnson, Pfizer, Portola, Sanofi; payments for lectures including speakers bureau services, payments for preparation of reports and payment for development of educational presentations from, Aspen, Bayer, Boehringer-Ingelheim, Bristol Myers Squibb, Daiichi, GlaxoSmithKline, Johnson and Johnson, Medscape, Pfizer and Portola. He has advised the UK Government Health Select Committee, the all-party working group on thrombosis, the Department of Health, and the NHS, on the prevention of VTE. He is also an advisor to Lifeblood: the thrombosis charity and is the founder of the European educational charity the Coalition to Prevent Venous Thromboembolism. Chris Arden and D. Wyn Davies have received consulting fees from Bristol Myers Squibb Pharmaceutical Ltd & Pfizer in relation to this study. Nathan Hill, Usman Farooqui, Michael Hurst, Kevin Pollock, and Belinda Sandler are employees of Bristol Myers Squibb UK. Michael Hurst was previously employed by Health Economics and Outcomes Research Ltd (HEOR). Jason Gordon, Carissa Dickerson, and Daniel Sugrue are employees of HEOR. HEOR were a paid consultant to Bristol Myers Squibb Pharmaceutical Ltd & Pfizer in connection with the development of this manuscript. Jennifer Rogers is an employee of PHASTAR. PHASTAR were a paid consultant to Bristol Myers Squibb Pharmaceutical Ltd & Pfizer in connection with the development of this manuscript. Christian Mallen and Sarah Lawton are employees of Keele University. Keele University were a paid consultant to Bristol Myers Squibb Pharmaceutical Ltd & Pfizer in connection with the development of this manuscript. CM is also funded by the National Institute for Health Research (NIHR) Applied Research Collaboration West Midlands and the NIHR School for Primary Care ResearchManjit Kainth is a General Practitioner at Primrose Lane Health Centre. Primrose Lane Health Centre received fees for involvement in the PULsE-AI trial from Bristol Myers Squibb Pharmaceutical Ltd & Pfizer.